Cargando…

Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively

Detalles Bibliográficos
Autores principales:	Dal Bello, Reinaldo, Pacchiardi, Kim, Chauvel, Clémentine, Adès, Lionel, Braun, Thorsten, Pasanisi, Justine, Fournier, Elise, Berthon, Céline, Clappier, Emmanuelle, Raffoux, Emmanuel, Lebon, Delphine, Cluzeau, Thomas, Roumier, Christophe, Plesa, Adriana, Celli-Lebras, Karine, Dombret, Hervé, Preudhomme, Claude, Mathis, Stéphanie, Puissant, Alexandre, Gardin, Claude, Itzykson, Raphael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771201/ https://www.ncbi.nlm.nih.gov/pubmed/36570694 http://dx.doi.org/10.1097/HS9.0000000000000819

Ejemplares similares

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
por: Duchmann, Matthieu, et al.
Publicado: (2022)

A multiparametric niche-like drug screening platform in acute myeloid leukemia
por: Dal Bello, Reinaldo, et al.
Publicado: (2022)

Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
por: Lambert, Juliette, et al.
Publicado: (2021)

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia
por: Duployez, Nicolas, et al.
Publicado: (2023)

Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)
por: Djamai, Hanane, et al.
Publicado: (2021)

Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use
por: Lesieur, Auriane, et al.
Publicado: (2020)

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study
por: Vasseur, Loïc, et al.
Publicado: (2023)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012)

B7‐H3 protein expression in acute myeloid leukemia
por: Guery, Thomas, et al.
Publicado: (2015)

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association
por: Debarri, Houria, et al.
Publicado: (2015)

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype
por: Fenwarth, Laurène, et al.
Publicado: (2019)

Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
por: Boudry, Augustin, et al.
Publicado: (2022)

Publisher Correction: Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
por: Boudry, Augustin, et al.
Publicado: (2022)

CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells
por: Touzet, Lucas, et al.
Publicado: (2019)

Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications
por: Fodil, Sofiane, et al.
Publicado: (2022)

Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study
por: Boyer, Thomas, et al.
Publicado: (2019)

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
por: Coudé, Marie-Magdelaine, et al.
Publicado: (2015)

SNP-array lesions in core binding factor acute myeloid leukemia
por: Duployez, Nicolas, et al.
Publicado: (2018)

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
por: Lambert, Juliette, et al.
Publicado: (2019)

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
por: Ferret, Yann, et al.
Publicado: (2018)

Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy
por: Wu, Hsin-Chieh, et al.
Publicado: (2021)

Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis
por: Cerrano, Marco, et al.
Publicado: (2023)

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
por: Lambert, Juliette, et al.
Publicado: (2014)

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies
por: Ades, Lionel, et al.
Publicado: (2017)

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia
por: Boyer, Thomas, et al.
Publicado: (2016)

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group
por: Adès, Lionel, et al.
Publicado: (2018)

Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults
por: Fenwarth, Laurène, et al.
Publicado: (2021)

Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL)
por: Berrou, Jeannig, et al.
Publicado: (2022)

Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience
por: Socie, Gerard, et al.
Publicado: (2023)

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively
por: Heiblig, Maël, et al.
Publicado: (2021)

French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study
por: Garnham, Andy, et al.
Publicado: (2023)

Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML
por: Dubois, Alix, et al.
Publicado: (2020)

SYK Regulates mTOR Signaling in AML
por: Carnevale, Julia, et al.
Publicado: (2013)

Arithmetics, geometry and conformal fields
por: Itzykson, Claude
Publicado: (1992)

New developments in Field Theory
por: Itzykson, Claude
Publicado: (1991)

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance
por: Emdal, Kristina B., et al.
Publicado: (2022)

A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis
por: Bond, Jonathan, et al.
Publicado: (2020)

Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing
por: Giraud, Mathieu, et al.
Publicado: (2014)

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial
por: Renneville, Aline, et al.
Publicado: (2014)

PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY
por: Raffoux, E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lmsqd2t0pn6ktu3clf0u5nohc8